top of page

This series is designed to provide investors with context to press releases directly from company management teams. It also provides the opportunity for companies to communicate directly to investors and elaborate on recent key news and highlight value driving milestones.


November 27, 2023

AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents


November 20, 2023

Next Generation Anthracycline


November 27, 2023

FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis

Artboard 1.png

November 14, 2023

Full Enrollment for VenoValve U.S. Pivotal Trial


October, 30, 2023

November, 1, 2023

GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression

NKGen Biotech Receives FDA Clearance of IND for SNK01 NK Cell Therapy to Treat Moderate Alzheimer's Disease


October, 18, 2023

Continuing Rapid Pace of
Enrollment with 229 Patients Enrolled


October, 17, 2023

Moleculin Doses First Patient in
Phase 2 Study for AML


September 27, 2023

Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement.


September 8, 2023

AREC"s ReElement Technologies Expands Executive Team

August 24, 2023

Recent Clinical Update on Potentially Pivotal Study of Berubicin for GBM

GRI Bio Enters into Asset Purchase Agreement for Sale of Legacy Asset, ADAIR

August 23, 2023

August 7, 2023

GRI Bio Presents Encouraging Preclinical Data of GRI-0803 in Lupus Nephritis

Access, Ideas, Clarity

A leading virtual platform providing investors with direct access to innovative companies, management teams and thought leaders

What This Means:

Contat Us
bottom of page